Integrating semaglutide into obesity management - a primary care perspective.
Postgrad Med · 2022
Last updated 2026-05-28A clinical approach for managing weight in primary care combines lifestyle changes with medication. The drug semaglutide, given as a once-weekly injection of 2.4 mg, can be used alongside diet and exercise to help with weight loss. The treatment requires careful dose escalation and ongoing monitoring to be effective.
AI summary of the abstract below.
| Journal | Postgrad Med, 2022 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.20 |
| NIH percentile | 13 |
| Molecules | semaglutide |
| Conditions studied | Obesity |
Abstract
This final article in the supplement aims to summarize a clinical approach for weight management geared toward primary care practitioners, offering practical advice about how to integrate weight management into day-to-day practice. To achieve long-term successful weight loss, a comprehensive multimodal approach is recommended, focusing on both lifestyle modification and appropriate use of therapy. Once-weekly subcutaneous semaglutide 2.4 mg is a novel treatment that can be used as an adjunct to lifestyle modification for the management of overweight and obesity. Key considerations are presented to support its optimal administration in conjunction with lifestyle modification, with a focus on assessing suitability and the importance of dose escalation and monitoring.
Verbatim abstract via PubMed 36691306 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.